MétaCan
Menu
← Back to cohort

Abstract A009: Mutation Matters: ATM and BRCA1/2 Shape Divergent Coagulopathy Programs in Pancreatic Cancer

2025· article· en· W4417201520 on OpenAlexaboutno aff
Allen Seylani, Shane Handelsman, Assal Sadighian

Bibliographic record

VenueClinical Cancer Research · 2025
Typearticle
Languageen
FieldMedicine
TopicPancreatic and Hepatic Oncology Research
Canadian institutionsnot available
Fundersnot available
KeywordsGermline mutationGermlineCoagulationMutationFactor VCoagulopathyFibrinogenPancreatic cancer

Abstract

fetched live from OpenAlex

Abstract Introduction: Early onset pancreatic ductal adenocarcinoma (PDAC) is on the rise, and inherited germline mutations in DNA damage repair pathways, including ATM and BRCA1/2, are increasingly recognized as important drivers. Cancer-associated coagulopathy is a leading cause of morbidity and mortality in PDAC, yet it remains unclear how distinct germline mutations influence thrombotic biology. Understanding whether ATM- versus BRCA1/2-driven PDAC tumors create unique coagulation signatures is critical for refining thromboprophylaxis strategies and for identifying novel therapeutic targets. Methods: We analyzed bulk RNA sequencing data from PDAC patient samples carrying germline ATM or BRCA1/2 mutations using the publicly available Gene Expression Omnibus dataset GSE193057. Raw counts were processed and normalized to transcripts per million (TPM). Genes related to the coagulation cascade, including clotting factors and fibrinogen subunits, were compared between mutation cohorts. Expression values were log2-transformed and averaged to highlight mutation-specific transcriptional differences across the coagulation pathway. Results: Transcriptomic analysis revealed divergent coagulation profiles. ATM-mutated tumors showed higher expression of Factor XI (log2 2.1 vs 0.2), Factor XIII A (4.6 vs 0.2), and fibrinogen chains FGA (1.0 vs 0.3), FGB (0.3 vs 0.7), and FGG (1.1 vs 0.2). In contrast, BRCA1/2-mutated tumors expressed markedly elevated Factor XII (8.9 vs 0.2), Factor VIII (3.2 vs 1.2), and Prothrombin (1.4 vs 0.1). Tissue Factor (Factor III) and Factor V were highly expressed in both cohorts, with greater proportion in BRCA1/2-mutated tumors (9.1 vs 6.9). Conclusions: Distinct germline contexts shape the coagulation landscape in PDAC through divergent mechanisms. ATM mutation appears to favor fibrin network stabilization via intrinsic pathway activation, whereas BRCA1/2 mutation preferentially enhances thrombin flux through contact and extrinsic pathway signaling. These mechanistic differences may underlie variable thrombotic risk across mutation carriers and highlight opportunities for mutation-specific thromboprophylaxis and mechanistic intervention. Citation Format: Allen Seylani, Allen Luo, Shane Handelsman, Assal Sadighian. Mutation Matters: ATM and BRCA1/2 Shape Divergent Coagulopathy Programs in Pancreatic Cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers—Knowledge Gaps and Research Opportunities; 2025 Dec 10-13; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(23_Suppl):Abstract nr A009.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.010
Threshold uncertainty score0.033

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0100.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.274
GPT teacher head0.546
Teacher spread0.272 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer Research→Same topicPancreatic and Hepatic Oncology Research→French-language works237,207→